drugset
drugset / Trial / NCT06793241

Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia

NCT06793241 ↗

Phase 0 Recruiting 15 enrolled Zhejiang University Yake Biotechnology Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

A Clinical Study on the Safety and Effectiveness of donor derived CD19 CAR-T Cells in the treatment of R/R B-cell acute lymphoblastic leukemia

Timeline

Start
2025-01-31
Primary completion
2028-01-31
Completion
2028-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject CD19 B-cell Acute Lymphoblastic Leukemia Targeted CAR T-cells Cell therapy — Intravenous

Indications

B-cell acute lymphoblastic leukemia